These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 22236405)

  • 21. Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides.
    Ballantyne CM; Jones PH; Kelly MT; Setze CM; Lele A; Thakker KM; Stolzenbach JC
    Cardiovasc Drugs Ther; 2011 Feb; 25(1):59-67. PubMed ID: 21416219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study.
    Roth EM; Rosenson RS; Carlson DM; Fukumoto SM; Setze CM; Blasetto JW; Khurmi NS; Stolzenbach JC; Williams LA
    Cardiovasc Drugs Ther; 2010 Dec; 24(5-6):421-8. PubMed ID: 20953684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus.
    Rosenson RS; Carlson DM; Kelly MT; Setze CM; Hirshberg B; Stolzenbach JC; Williams LA
    Cardiovasc Drugs Ther; 2011 Feb; 25(1):47-57. PubMed ID: 21174145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.
    Moutzouri E; Kei A; Elisaf MS; Milionis HJ
    Vasc Health Risk Manag; 2010 Aug; 6():525-39. PubMed ID: 20730069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study.
    Kipnes MS; Roth EM; Rhyne JM; Setze CM; Lele A; Kelly MT; Sleep DJ; Stolzenbach JC
    Clin Drug Investig; 2010; 30(1):51-61. PubMed ID: 19995098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
    Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A review of time courses and predictors of lipid changes with fenofibric acid-statin combination.
    Filippatos TD
    Cardiovasc Drugs Ther; 2012 Jun; 26(3):245-55. PubMed ID: 22592524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The association of S447X and Hind III polymorphism in the lipoprotein lipase gene with dyslipidemia of the metabolic syndrome in patients with essential hypertension].
    Liu A; Li L; Cao W; Shan S; Lu J; Guo X; Hu Y
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Apr; 22(2):151-7. PubMed ID: 15793775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systematic literature review and meta-analysis of dual therapy with fenofibrate or fenofibric acid and a statin versus a double or equivalent dose of statin monotherapy.
    Ouwens MJ; Nauta J; Ansquer JC; Driessen S
    Curr Med Res Opin; 2015 Dec; 31(12):2273-85. PubMed ID: 26397380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia.
    Yang LP; Keating GM
    Am J Cardiovasc Drugs; 2009; 9(6):401-9. PubMed ID: 19929038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.
    Roth EM; Rosenson RS; Jones PH; Davidson MH; Kelly MT; Setze CM; Lele A; Thakker K
    J Clin Lipidol; 2012; 6(6):534-44. PubMed ID: 23312049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial.
    Davidson M; Rosenson RS; Maki KC; Nicholls SJ; Ballantyne CM; Setze C; Carlson DM; Stolzenbach J
    Cardiovasc Drugs Ther; 2012 Aug; 26(4):349-58. PubMed ID: 22622962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia.
    Alagona P
    Vasc Health Risk Manag; 2010 May; 6():351-62. PubMed ID: 20531954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics.
    Qamar A; Khetarpal SA; Khera AV; Qasim A; Rader DJ; Reilly MP
    Arterioscler Thromb Vasc Biol; 2015 Aug; 35(8):1880-8. PubMed ID: 26069232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New Fixed-Dose Combinations of Fenofibrate/Simvastatin Therapy Significantly Improve the Lipid Profile of High-Risk Patients with Mixed Dyslipidemia Versus Monotherapies.
    Foucher C; Aubonnet P; Reichert P; Berli M; Schaeffer A; Calvo Vargas CG; Lochocka A; Belenky D; Koch HF;
    Cardiovasc Ther; 2015 Dec; 33(6):329-37. PubMed ID: 26227087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
    Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
    Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
    Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP;
    JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.